Skip to content
Keylika logo

Keylika

Keylika is a YC Summer 2022 (S22) company. Based in Walnut Creek, CA, USA. Team of 1.

  • AI-powered Drug Discovery
  • Medical Devices
  • Drug Delivery
  • Nanotechnology
  • Therapeutics

About Keylika

GPAgent's own fund-neutral profile, written from public information. Updated Oct 5, 2026.

Summary

Keylika develops a prescription transdermal iron patch, NistuFe, to treat iron deficiency anemia in patients who cannot tolerate oral iron supplements or IV infusions. The patch delivers a proprietary small-molecule iron compound directly into the bloodstream through the skin, eliminating the gastrointestinal side effects of oral iron and the cost and clinical risks of intravenous treatment. It replaces both oral supplementation and infusion-based care for a condition affecting hundreds of millions of people globally.

Go-to-market

The target patient populations include women, children, and patients with comorbidities such as inflammatory bowel disease, chronic kidney disease, and post-bariatric surgery. The product is a prescription therapy, positioning it for physician-driven adoption once regulatory approval is obtained.

From the Y Combinator listing

How Keylika describes itself in Y Combinator's public directory. Original listing (opens in a new tab)

Redefining the Standard of Care for Iron Deficiency Anemia

Keylika is an early stage biopharma startup developing metal-based drugs using a platform synthesis technology to treat unmet medical needs. We then administer these drugs using proven delivery technologies to effect the best clinical outcomes. Our first product is a small molecule iron drug (new molecular entity) delivered by a wearable skin patch to treat Iron Deficiency Anemia (IDA), with significantly higher safety, efficacy and tolerability over existing treatments. This is poised to be a best-in-class, potentially breakthrough therapy for treating iron deficiency without any GI side-effects (eg. nausea, constipation, diarrhea, etc.) typically associated with oral iron supplements, and without the risks, costs and side-effects associated with IV iron infusions. When approved, Keylika’s proprietary transdermal iron will be the world's first prescription iron patch. Iron deficiency is a hugely understated problem affecting about 1.6 billion people worldwide and more than 30 million in the US alone, translating to a $17B US market.

Facts

Industry
Healthcare / Healthcare -> Therapeutics
Location
Walnut Creek, CA, USA
Team size
1
Status
Active
Stage
Early

Founders (2)

Score every batch against your own thesis

GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.

How Accelerator intelligence works